Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout-Reference-Cited by-同舟云学术

Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout

Published:2017-08-17 Issue:1 Volume:19 Page:
ISSN:1478-6362
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Calabrese Leonard H.,Kavanaugh Arthur,Yeo Anthony E.,Lipsky Peter E.

Funder

Horizon Pharma

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13075-017-1396-8.pdf

Reference16 articles.

1. Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007;56:1021–8.

2. KRYSTEXXA™ (pegloticase) Injection, for intravenous infusion. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125293s0000lbl.pdf . Accessed 3 Aug 2017.

3. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711–20.

4. Barah HS, Yood RA, Ottery FD, Sundy JS, Becker MA. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014;20:427–32.

5. Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16:R60.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy;Arthritis Care & Research;2024-06-23

2. PEGylated porcine–human recombinant uricase: A novel fusion protein with improved efficacy and safety for the treatment of hyperuricemia and renal complications;Open Life Sciences;2024-01-01

3. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG;Vaccine;2023-07

4. Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients;Vaccine;2023-07

5. Pegloticase in Uncontrolled Gout;Journal of Infusion Nursing;2023-07